Single-fraction stereotactic radiosurgery of meningeal hemangiopericytomas

Meningeal hemangiopericytomas (M-HPC) are challenging tumors with a high rate of recurrence despite surgical resection and external beam radiotherapy (EBRT). To better understand the role of single-fraction stereotactic radiosurgery (SRS) for patients with M-HPC, we reviewed our experience with 22 p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2014-10, Vol.120 (1), p.95-102
Main Authors: Copeland, William R., Link, Michael J., Stafford, Scott L., Pollock, Bruce E.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Clinical Study
Dose Fractionation
Female
Follow-Up Studies
Hemangiopericytoma - mortality
Hemangiopericytoma - pathology
Hemangiopericytoma - surgery
Humans
Male
Medicine
Medicine & Public Health
Meningeal Neoplasms - mortality
Meningeal Neoplasms - pathology
Meningeal Neoplasms - surgery
Middle Aged
Neoplasm Staging
Neurology
Oncology
Postoperative Complications
Prognosis
Radiosurgery
Survival Rate
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Meningeal hemangiopericytomas (M-HPC) are challenging tumors with a high rate of recurrence despite surgical resection and external beam radiotherapy (EBRT). To better understand the role of single-fraction stereotactic radiosurgery (SRS) for patients with M-HPC, we reviewed our experience with 22 patients (12 men, 10 women) from 1990 until 2010. Twelve patients (55 %) underwent a single SRS procedure, whereas 10 patients (45 %) had more than one SRS procedure (range 2–6). In total, 47 SRS procedures were performed to treat 64 tumors. Fourteen patients (64 %) had undergone prior EBRT (median dose, 56.0 Gy). Follow-up after the initial SRS (median, 66 months) was censored at the time of death ( n  = 15) or last clinical evaluation ( n  = 7). Eleven patients (50 %) died of intracranial tumor progression ( n  = 10) or treatment-related complications ( n  = 1). One patient (5 %) died of systemic disease progression. Disease-specific survival (DSS) at 1-, 3- and 5-years after SRS was 96, 82, and 61 %, respectively. Prior EBRT (HR 9.0, 95 % CI 1.1–78.1, p  
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-014-1521-3